Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
about
Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationalIMOP: randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptabilityScreening for lung cancerCombination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Multi-agent chemotherapy for early breast cancerHome-based support for disadvantaged adult mothersHome-based support for disadvantaged adult mothersInterventions for the treatment of Morton's neuromaNonabsorbable disaccharides for hepatic encephalopathyParacetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritisArtificial and bioartificial support systems for liver failureScreening for lung cancerBias in case-control studies. A reviewThe VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular diseaseCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsClassification of traumatic brain injury for targeted therapiesLong-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group studyAn historical perspective on meta-analysis: dealing quantitatively with varying study resultsDeoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomasInterim analyses of data as they accumulate in laboratory experimentationThe CRASH trial protocol (Corticosteroid randomisation after significant head injury) [ISRCTN74459797]The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study MethodologiesVHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversyA prospective examination of octreotide-induced gall-bladder changes in acromegalyACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effectsNevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trialComparison of isoflurane and sevoflurane in cardiac surgery: a randomized non-inferiority comparative effectiveness trialPressure and volume limited ventilation for the ventilatory management of patients with acute lung injury: a systematic review and meta-analysisMethotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good RLong-term drug prevention trials.International randomised controlled trial of patient triggered ventilation in neonatal respiratory distress syndrome.Interim analyses of survival data in cancer clinical trials.Assessment and comparison of prognostic classification schemes for survival data.When enough is enough: how the decision was made to stop the FEAST trial: data and safety monitoring in an African trial of Fluid Expansion As Supportive Therapy (FEAST) for critically ill childrenRole of the Data and Safety Monitoring Committee (DSMC).Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the diseaseMulticolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome.
P2860
Q21203739-12EF7637-B0AF-4F16-97C1-5262715CD7B2Q21261343-0A69C31A-3FE6-489E-A407-FC8CA40C7843Q24201867-F63D8B7F-4EBC-400B-BD7C-1024A4A944ABQ24235846-F6C6C798-02F9-4F0E-87A7-3418834FA1A3Q24241534-1D67A38D-0E3E-4E54-B2A0-C62AFECF32A5Q24243324-17B6EF8E-E5EC-451B-AF75-4A16B638E135Q24244013-3E50DFF2-4CA1-451A-8C78-2FD5A759D59BQ24246694-4B2E03F8-3683-4814-974C-49169F2E0DA0Q24247141-2197C05D-06FC-4315-8A9B-59D6D62BCD04Q24247410-C3152560-BBB3-40B4-9576-A089FC0B0BA2Q24247462-EA925686-4F6E-4022-931A-2FDE55799DEEQ24247464-28EFD49F-30AA-4864-B76E-45AD85F4969AQ24519056-FA0FD036-DD5A-40AA-978E-19E66CD17FBBQ24613094-B38D6FB8-C034-4952-AB4F-3CFF1C748D61Q24614627-9D360C1A-0A99-4A10-967D-BABB6B7A0BE6Q24656273-A5E9800B-6F25-4714-8431-E28D6C4FC20EQ24658339-39B3380E-B3D2-4020-9AAC-BF8870256D8CQ24670361-4C0EB687-4028-4BC8-BBB6-3A9BC0BF7760Q24678646-127D09CC-345D-44F5-9AE5-A53C4B230A5FQ24799590-DADE2F26-06D2-4C57-9A4A-CF5B8D942077Q24800159-484EEC73-A802-444E-82BD-E3B07F59C075Q24804541-B7B9B225-5095-49EC-887E-60663C768095Q26767271-FB59DED0-1AD7-4744-B91A-07C641950166Q27824781-68961029-C252-46D6-90D2-5F378D2D914AQ28305315-1092B1D7-34C7-4604-87C2-F3FAB2B02408Q28319481-D277A1BF-C30D-4A29-99CE-E2AB0EAE43B9Q28362780-4303E9DA-2CBB-4A2C-9B68-40D8D225E388Q28483969-A3D4E6A3-C3B8-4845-A838-6C4888CD6681Q28484207-EAE44E1E-A0FF-4B5B-82E6-62BD880D4E4FQ28595767-41837F06-F392-4088-B884-70140A4A8C2BQ28743204-4558BB5B-19EB-4A17-AEE8-34F9226B4156Q30357731-3C44308D-DB1E-4286-BE77-2267A3357CE5Q30368543-09BD58CB-20BE-4CE6-9D12-5AF8C36F28DFQ30478522-F53D563A-6FA7-49A6-855B-1E873E948AFCQ30558970-06D4B916-BAFA-4049-9B82-949B6EB8155FQ30581228-3467C702-3A29-4F32-9001-DC3E8029DBE6Q30607444-7519E858-887E-4D30-9128-304C3ACAF365Q30731720-7882EBE9-B2A0-48E6-B80F-61C99416692EQ30747351-9033CFB3-6433-412E-9669-AEE7BDF4BEA7Q30819544-81874B99-D8A6-4658-ADB8-49AB62C17B15
P2860
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
description
1976 nî lūn-bûn
@nan
1976 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
Design and analysis of randomi ...... nt. I. Introduction and design
@ast
Design and analysis of randomi ...... nt. I. Introduction and design
@en
Design and analysis of randomi ...... nt. I. Introduction and design
@nl
type
label
Design and analysis of randomi ...... nt. I. Introduction and design
@ast
Design and analysis of randomi ...... nt. I. Introduction and design
@en
Design and analysis of randomi ...... nt. I. Introduction and design
@nl
prefLabel
Design and analysis of randomi ...... nt. I. Introduction and design
@ast
Design and analysis of randomi ...... nt. I. Introduction and design
@en
Design and analysis of randomi ...... nt. I. Introduction and design
@nl
P2093
P2860
P3181
P356
P1476
Design and analysis of randomi ...... nt. I. Introduction and design
@en
P2093
K McPherson
N E Breslow
P Armitage
S V Howard
P2860
P2888
P304
P3181
P356
10.1038/BJC.1976.220
P407
P50
P577
1976-12-01T00:00:00Z
P5875
P6179
1042182549